Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD...
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 19, 2023
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil. It increases central sexual motivation and physiological sexual responses.
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2023
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido (sildenafil) intends to increase central sexual motivation and physiological sexual responses. It consists of a novel combination tablet containing a testosterone coating for sublingual administration and an inner-core component made of the PDE-5...
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 02, 2023
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido (sildenafil) is a unique therapeutic concept, both by its combination of testosterone and sildenafil, as well as by its dual route, dual release, fixed dose system, and as such achieving the optimal synergy of both active ingredients.
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2022
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido (sildenafil) increases central sexual motivation and physiological sexual responses, such as swelling of vaginal erectile tissue and lubrication.
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2022
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $8.5 million
Deal Type : Financing
Details : The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints.
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 29, 2022
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $8.5 million
Deal Type : Financing
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.
Brand Name : Lybrido
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?